# NIH Reporter #5R01AR085258-02

Circulating cell free tumor DNA (ctDNA) in patients with immune checkpoint inhibitor associated inflammatory arthritis (ICI-IA): developing a biomarker to assess immunosuppressive drug safety

**Recipient:** Hospital for Special Surgery

**Award Amount:** $206,329.00
**Ceiling:** $206,329.00

**Awarded:** August 19, 2026

**Identifier:** 5R01AR085258-02

This NIH-funded research project evaluates ctDNA as a biomarker for cancer progression and the safety of immunosuppressive treatment in patients with ICI-associated inflammatory arthritis.

### Description

The project measures circulating cell-free tumor DNA in patients with immune checkpoint inhibitor-associated inflammatory arthritis to assess whether it can indicate cancer progression and how it changes after immunosuppressive treatment.

[View original record](https://reporter.nih.gov/search/47CiHD0bJ0u2LtDABS0zbg/project-details/11411495)